How Biotech Cos. Can Utilize Synthetic Royalty Financing
By Todd Trattner and Ryan Murr · February 1, 2024, 5:31 PM EST
Following the capital markets boom fueled by the Fed's accommodating monetary policy in 2020 and 2021, the biotech sector suffered nearly a 50% drop over a 12-month period from February 2021...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login